Curi Capital LLC Has $19.19 Million Position in The Cooper Companies, Inc. $COO

Curi Capital LLC lessened its holdings in The Cooper Companies, Inc. (NASDAQ:COO) by 24.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 269,697 shares of the medical device company’s stock after selling 88,975 shares during the quarter. Curi Capital LLC’s holdings in Cooper Companies were worth $19,192,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in COO. Sustainable Growth Advisers LP acquired a new stake in shares of Cooper Companies during the 2nd quarter valued at about $240,881,000. Ameriprise Financial Inc. boosted its holdings in Cooper Companies by 98.8% during the second quarter. Ameriprise Financial Inc. now owns 3,388,413 shares of the medical device company’s stock valued at $241,120,000 after purchasing an additional 1,683,561 shares in the last quarter. Franklin Resources Inc. boosted its holdings in Cooper Companies by 7,723.3% during the second quarter. Franklin Resources Inc. now owns 1,569,512 shares of the medical device company’s stock valued at $111,686,000 after purchasing an additional 1,549,450 shares in the last quarter. Findlay Park Partners LLP grew its stake in shares of Cooper Companies by 312.5% in the 2nd quarter. Findlay Park Partners LLP now owns 1,815,900 shares of the medical device company’s stock valued at $129,219,000 after purchasing an additional 1,375,657 shares during the period. Finally, Soundwatch Capital LLC acquired a new position in shares of Cooper Companies in the 2nd quarter worth approximately $607,000. Institutional investors and hedge funds own 24.39% of the company’s stock.

Insider Activity

In related news, Director Lawrence Erik Kurzius purchased 2,000 shares of the firm’s stock in a transaction dated Monday, September 29th. The shares were acquired at an average cost of $68.39 per share, with a total value of $136,780.00. Following the completion of the purchase, the director directly owned 5,777 shares of the company’s stock, valued at $395,089.03. This trade represents a 52.95% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 1.98% of the company’s stock.

Cooper Companies Stock Performance

Shares of NASDAQ:COO opened at $82.08 on Friday. The business has a fifty day moving average of $73.44 and a 200-day moving average of $71.76. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.13 and a current ratio of 1.89. The Cooper Companies, Inc. has a twelve month low of $61.78 and a twelve month high of $100.24. The firm has a market cap of $16.09 billion, a PE ratio of 43.66, a price-to-earnings-growth ratio of 2.34 and a beta of 1.05.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings results on Thursday, December 4th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.11 by $0.04. The business had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.06 billion. Cooper Companies had a net margin of 9.16% and a return on equity of 10.02%. The firm’s quarterly revenue was up 4.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.04 EPS. Cooper Companies has set its FY 2026 guidance at 4.450-4.600 EPS and its Q1 2026 guidance at 1.020-1.040 EPS. On average, equities research analysts predict that The Cooper Companies, Inc. will post 3.98 EPS for the current fiscal year.

Cooper Companies declared that its board has initiated a stock repurchase program on Wednesday, September 17th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the medical device company to buy up to 15.4% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s board believes its shares are undervalued.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on COO. Piper Sandler reaffirmed an “overweight” rating and issued a $94.00 price target (up previously from $83.00) on shares of Cooper Companies in a research note on Friday, December 5th. Mizuho set a $100.00 target price on shares of Cooper Companies and gave the company an “outperform” rating in a research note on Friday, December 5th. KeyCorp reaffirmed a “sector weight” rating on shares of Cooper Companies in a report on Friday, December 5th. Barclays reiterated an “overweight” rating and set a $91.00 target price on shares of Cooper Companies in a research report on Monday. Finally, Robert W. Baird boosted their price target on shares of Cooper Companies from $85.00 to $98.00 and gave the company an “outperform” rating in a research report on Friday, December 5th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Cooper Companies currently has an average rating of “Moderate Buy” and a consensus price target of $90.15.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.